S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video) (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:RAIN

Rain Oncology (RAIN) Stock Forecast, Price & News

$0.86
+0.01 (+1.17%)
(As of 09/29/2023 ET)
Compare
Today's Range
$0.84
▼
$0.87
50-Day Range
$0.82
▼
$1.41
52-Week Range
$0.82
▼
$14.48
Volume
185,618 shs
Average Volume
146,009 shs
Market Capitalization
$31.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Rain Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
1,872.6% Upside
$17.00 Price Target
Short Interest
Healthy
3.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of Rain Oncology in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.67) to ($0.72) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

372nd out of 972 stocks

Pharmaceutical Preparations Industry

154th out of 445 stocks

See Top Rated MarketRank™ Stocks Here

RAIN stock logo

About Rain Oncology (NASDAQ:RAIN) Stock

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

RAIN Price History

RAIN Stock News Headlines

October 1, 2023 | msn.com
Winship 5K to support local cancer research
September 29, 2023 | msn.com
Voluntary relocation fund created for Houston-area residents living near cancer cluster
October 1, 2023 | Porter and Company (Ad)
Top Analyst Exposes Imminent Crisis Hurtling Towards America
The man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…
September 28, 2023 | news.yahoo.com
Tiny plastic particles have reached clouds, contaminating ‘everything we eat’ via rain, study warns
September 27, 2023 | news.yahoo.com
Morning sprinkles followed by strong storms and heavy rain in the afternoon
September 27, 2023 | msn.com
Bingo for Breast Cancer fundraiser happening Thursday
September 26, 2023 | msn.com
Prostate cancer awareness month underscores importance of getting screened
September 25, 2023 | msn.com
‘Today' show's Craig Melvin, celebs raise $1.2 million in CT to fight colorectal cancer
October 1, 2023 | Porter and Company (Ad)
Top Analyst Exposes Imminent Crisis Hurtling Towards America
The man who warned of the dot-com blow up, the 2008 housing collapse, and the loss of America’s AAA rating makes a shocking prediction…
September 25, 2023 | msn.com
Cancer institute asks for help over limited space
September 25, 2023 | msn.com
Iowa Gov. Kim Reynolds’ husband diagnosed with lung cancer
September 25, 2023 | msn.com
FIRST ALERT FORECAST: Rain Expected as we Begin our Workweek
September 23, 2023 | msn.com
Blue September: Bay of Plenty prostate cancer survivor urges men to get a PSA test
September 22, 2023 | msn.com
Steady rain Saturday in southern New Hampshire; track of Potential Tropical Cyclone 16 being watched
September 21, 2023 | msn.com
Rain ahead; Standing Rock poor roads; lion statue stolen
September 21, 2023 | mirror.co.uk
'Cancer nearly took everything from me - now I'm hiking up mountains'
September 21, 2023 | americanbankingnews.com
Rain Oncology Inc. (NASDAQ:RAIN) Receives $17.00 Average Price Target from Brokerages
September 20, 2023 | usatoday.com
Arsenal makes winning return to Champions League by beating PSV Eindhoven 4-0 in the rain
September 18, 2023 | msn.com
Michigan cancer survivor inspires other kids battling cancer
September 18, 2023 | msn.com
Citigroup Maintains Rain Oncology (RAIN) Neutral Recommendation
September 14, 2023 | uk.finance.yahoo.com
‘No rain, no winter, no rivers’: This ancient European lake is receding - and it could be disastrous
September 12, 2023 | news.yahoo.com
Atmospheric acid test: Can the successes of reducing acid rain apply to the current climate crisis?
September 12, 2023 | msn.com
Jonnie Irwin Spending Time with Family Despite Being 'Pretty Unwell' amid Terminal Cancer
September 11, 2023 | stockhouse.com
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Rain Oncology Inc. (RAIN)
September 11, 2023 | markets.businessinsider.com
SHAREHOLDER ALERT: Potential Recovery for Rain Oncology Inc. (RAIN) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit
September 11, 2023 | uk.news.yahoo.com
Envirovue colleagues complete Three Peaks Challenge for cancer charity
September 10, 2023 | msn.com
Doctors warn of the most common areas of the body for skin cancer symptoms to appear
See More Headlines
Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAIN Company Calendar

Last Earnings
8/10/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAIN
CUSIP
N/A
CIK
1724979
Web
www.rainthera.com
Phone
510-953-5559
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,872.6%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,720,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-91.93%
Return on Assets
-76.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.96
Quick Ratio
4.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.11 per share
Price / Book
0.28

Miscellaneous

Outstanding Shares
36,376,000
Free Float
30,047,000
Market Cap
$31.35 million
Optionable
Not Optionable
Beta
0.21
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 48)
    Co-Founder, CEO & Chairman
    Comp: $959.75k
  • Dr. Robert C. Doebele M.D. (Age 52)
    Ph.D., Co-Founder, Chairman of Scientific Advisory Board, Pres & CSO and Chief Medical Officer
    Comp: $700.56k
  • Ms. Josephine Bruce (Age 44)
    Principal Financial & Accounting officer
  • Ms. Theresa O'Connell M.S.
    Director of Corp. Devel. & Operations
  • Mr. Erik Atkisson (Age 51)
    Gen. Counsel & Chief Compliance Officer
  • Ms. Charmi Turner
    VP of People & Culture
  • Ms. Vijaya Tirunagaru Ph.D.
    Sr. VP & Head of Research
  • Dr. Nora Ku M.D.
    MD & VP of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RAIN Stock - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings or view top-rated stocks.

What is Rain Oncology's stock price forecast for 2023?

12 analysts have issued twelve-month price targets for Rain Oncology's stock. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,872.6% from the stock's current price.
View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.

How have RAIN shares performed in 2023?

Rain Oncology's stock was trading at $8.00 at the start of the year. Since then, RAIN stock has decreased by 89.2% and is now trading at $0.8618.
View the best growth stocks for 2023 here.

Are investors shorting Rain Oncology?

Rain Oncology saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 705,700 shares, a decrease of 18.1% from the August 31st total of 861,800 shares. Based on an average trading volume of 302,100 shares, the short-interest ratio is presently 2.3 days. Approximately 3.5% of the company's stock are short sold.
View Rain Oncology's Short Interest.

When is Rain Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our RAIN earnings forecast.

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by $0.12.

What ETFs hold Rain Oncology's stock?

ETFs with the largest weight of Rain Oncology (NASDAQ:RAIN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), Horizon Kinetics Medical ETF (MEDX),

When did Rain Oncology IPO?

(RAIN) raised $126 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

What is Rain Oncology's stock symbol?

Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN."

How do I buy shares of Rain Oncology?

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rain Oncology's stock price today?

One share of RAIN stock can currently be purchased for approximately $0.86.

How much money does Rain Oncology make?

Rain Oncology (NASDAQ:RAIN) has a market capitalization of $31.35 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How can I contact Rain Oncology?

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.

This page (NASDAQ:RAIN) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -